|
|
Vol. 12.09 – 25 May, 2026
|
|
|
|
|
|
|
Scientists identified the small MAF family transcription factor MAFG as a critical regulator of MITF activity and melanoma cell state plasticity. [Nature Communications]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
DERMAL STEM CELLS & TISSUE REGENERATION
|
|
|
|
|
|
Investigators showed that H3K9me3 deposition is dynamic during epidermis morphogenesis and essential for lineage diversification.
[Nature Communications]
|
|
|
|
|
|
Short-term sodium dodecyl sulfate exposure rapidly disrupts human skin barrier integrity through oxidative stress-driven suppression of structural/immune mediators and activation of stress/remodeling pathways.
[Allergy]
|
|
|
|
|
|
Researchers provided a greater understanding of, and potential strategies to refine, essential human fibroblast culture models.
[iScience]
|
|
|
|
|
|
|
|
The authors found that both compounds demonstrated potent anti-proliferative activity against NRAS-mutated melanoma cell lines and robust anti-tumor activity against preclinical melanoma models.
[Cancer Research]
|
|
|
|
|
|
Scientists evaluated drug combinations in patients with metastatic melanoma and cutaneous squamous cell carcinoma. Pegenzileukin was given at two dose levels during dose escalation and the recommended Phase II dose during dose expansion, while cemiplimab was given at a dose of 350 mg.
[Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
Researchers demonstrated a novel facet of GSDME as an epigenetic modifier that promotes melanoma development through the regulation of the centriole biogenesis regulator PLK4. [Cell Death & Differentiation]
|
|
|
|
|
|
|
|
The authors systematically elaborate the cellular and molecular mechanisms underlying skin photoaging. This review also details the pivotal roles of and reciprocal crosstalk among fibroblasts, keratinocytes, melanocytes, and various immune cells. [Bioscience Trends]
|
|
|
|
|
|
|
|
Abeona Therapeutics, Inc. announced activation of the Children’s Hospital of Philadelphia as the sixth Qualified Treatment Center for the administration of ZEVASKYN gene-modified cellular sheets. [Abeona Therapeutics, Inc.]
|
|
|
|
|
|
|
|
July 12-16, 2026 Washington, DC, United States
|
|
|
|
|
|
|
|
|
|
|
Imperial College London – London, England, United Kingdom
|
|
|
|
|
|
|
University Hospital Würzburg – Würzburg, Germany
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
University of Virginia – Charlottesville, Virginia, United States
|
|
|
|
|
|
|
Heidelberg University – Heidelberg, Germany
|
|
|
|
|
|